The Histone Deacetylase Inhibitor, Vorinostat, Reduces Tumor Growth at the Metastatic Bone Site and Associated Osteolysis, but Promotes Normal Bone Loss
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Vorinostat, an oral histone deacetylase inhibitor with antitumor activity, is in clinical trials for hematologic and solid tumors that metastasize and compromise bone structure. Consequently, there is a requirement to establish the effects of vorinostat on tumor growth within bone. Breast (MDA-231) and prostate (PC3) cancer cells were injected into tibias of SCID/NCr mice and the effects of vorinostat on tumor growth and osteolytic disease were assessed by radiography, micro-computed tomography, and histologic and molecular analyses. Vorinostat-treated and control mice without tumors were also examined. Tumor growth in bone was reduced ∼33% by vorinostat with inhibited osteolysis in the first few weeks of the experiment. However, osteolysis became more severe in both the vehicle and vorinostat-treated groups. Vorinostat increased the expression of tumor-derived factors promoting bone resorption, including PTHrP, IL-8, and osteopontin. After 4 weeks of vorinostat therapy, the non–tumor-bearing contralateral femurs and limbs from vorinostat-treated tumor-free SCID mice showed significant bone loss (50% volume density of controls). Thus, our studies indicate that vorinostat effectively inhibits tumor growth in bone, but has a negative systemic effect reducing normal trabecular bone mass. Vorinostat treatment reduces tumor growth in bone and accompanying osteolytic disease as a result of decreased tumor burden in bone. However, vorinostat can promote osteopenia throughout the skeleton independent of tumor cell activity. Mol Cancer Ther; 9(12); 3210–20. ©2010 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542 · cited 1×
“transcription include inducing acetylation of histones, transcription factors, and other proteins (36).”
BackgroundRichon, V. M., Sandhoff, T. W., Rifkind, R. A., & Marks, P. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180316197 · Cited by 1,090
Pathogenesis of myeloma bone disease
Roodman, G. D. (2009) · Leukemia · doi:10.1038/leu.2008.336 · Cited by 398
Cited by
Xu, S., De Veirman, K., Evans, H., Santini, G. C., Vande Broek, I., Leleu, X., De Becker, A., Van Camp, B., Croucher, P., Vanderkerken, K., et al. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2012.182 · Cited by 64
Behera, J., Kelly, K. E., Voor, M. J., Metreveli, N., Tyagi, S. C., & Tyagi, N. (2018) · Scientific Reports · doi:10.1038/s41598-018-33149-9 · Cited by 59
K V, A., Madhana, R. M., Bais, A. K., Singh, V. B., Malik, A., Sinha, S., Lahkar, M., Kumar, P., & Samudrala, P. K. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00315 · Cited by 15
Metadata
- Authors
- Pratap, J., Akech, J., Wixted, J. J., Szabo, G., Hussain, S., McGee-Lawrence, M. E., Li, X., Bedard, K., Dhillon, R. J., van Wijnen, A. J., Stein, J. L., Stein, G. S., Westendorf, J. J., & Lian, J. B.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2010-12-01
- Volume
- 9
- Issue
- 12
- Pages
- 3210-3220
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2129643900
- Cited by
- 52
- References
- 3
- FWCI
- 2.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Histone Deacetylase Inhibitor, Vorinostat, Reduces Tumor Growth at the Metastatic Bone Site and Associated Osteolysis, but Promotes Normal Bone Loss. https://app.cochat.ai/papers/10.1158/1535-7163.mct-10-0572
- The paper
- Pratap, J., Akech, J., Wixted, J. J., Szabo, G., Hussain, S., McGee-Lawrence, M. E., Li, X., Bedard, K., Dhillon, R. J., van Wijnen, A. J., Stein, J. L., Stein, G. S., Westendorf, J. J., & Lian, J. B. (2010). The Histone Deacetylase Inhibitor, Vorinostat, Reduces Tumor Growth at the Metastatic Bone Site and Associated Osteolysis, but Promotes Normal Bone Loss. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-10-0572
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.